HRP20041060B1 - (imidazol-1-yl-methyl)-pyridazine as nmda receptor blocker - Google Patents

(imidazol-1-yl-methyl)-pyridazine as nmda receptor blocker

Info

Publication number
HRP20041060B1
HRP20041060B1 HRP20041060A HRP20041060B1 HR P20041060 B1 HRP20041060 B1 HR P20041060B1 HR P20041060 A HRP20041060 A HR P20041060A HR P20041060 B1 HRP20041060 B1 HR P20041060B1
Authority
HR
Croatia
Prior art keywords
pyridazine
imidazol
methyl
nmda receptor
receptor blocker
Prior art date
Application number
Other languages
English (en)
Inventor
Bernd Buettelmann
Marie-Paule Heitz Neidhart
Georg Jaeschke
Emmanuel Pinard
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HRP20041060A2 publication Critical patent/HRP20041060A2/xx
Publication of HRP20041060B1 publication Critical patent/HRP20041060B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HR20041060 2002-05-16 2003-05-16 (imidazol-1-yl-methyl)-pyridazine as nmda receptor blocker HRP20041060B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02010217 2002-05-16
PCT/EP2003/005151 WO2003097637A1 (en) 2002-05-16 2003-05-16 (imidazol-1-yl-methyl)-pyridazine as nmda receptor blocker

Publications (2)

Publication Number Publication Date
HRP20041060A2 HRP20041060A2 (en) 2005-06-30
HRP20041060B1 true HRP20041060B1 (en) 2012-11-30

Family

ID=29433072

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20041060 HRP20041060B1 (en) 2002-05-16 2003-05-16 (imidazol-1-yl-methyl)-pyridazine as nmda receptor blocker

Country Status (30)

Country Link
US (1) US7005432B2 (bs)
EP (1) EP1506190B1 (bs)
JP (1) JP4267569B2 (bs)
KR (1) KR100632868B1 (bs)
CN (1) CN1312151C (bs)
AR (1) AR040010A1 (bs)
AT (1) ATE329912T1 (bs)
AU (1) AU2003242542B2 (bs)
BR (1) BR0311177A (bs)
CA (1) CA2485926C (bs)
CL (1) CL2004001251A1 (bs)
CY (1) CY1105159T1 (bs)
DE (1) DE60306152T2 (bs)
DK (1) DK1506190T3 (bs)
ES (1) ES2265581T3 (bs)
HR (1) HRP20041060B1 (bs)
IL (1) IL164922A (bs)
MA (1) MA27117A1 (bs)
ME (1) MEP76708A (bs)
MX (1) MXPA04011253A (bs)
NO (1) NO329605B1 (bs)
NZ (1) NZ536310A (bs)
PL (1) PL211340B1 (bs)
PT (1) PT1506190E (bs)
RS (1) RS51200B (bs)
RU (1) RU2317294C2 (bs)
SI (1) SI1506190T1 (bs)
TN (1) TNSN04224A1 (bs)
WO (1) WO2003097637A1 (bs)
ZA (1) ZA200408789B (bs)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
GB0218876D0 (en) * 2002-08-13 2002-09-25 Merck Sharp & Dohme Therapeutic agents
CN100579579C (zh) * 2002-10-01 2010-01-13 诺华疫苗和诊断公司 抗癌及抗感染性疾病组合物及其使用方法
WO2006117052A1 (de) * 2005-05-03 2006-11-09 Merck Patent Gmbh Organische elektrolumineszenzvorrichtung und in deren herstellung verwendete boronsäure- und borinsäure-derivate
US20090054392A1 (en) * 2007-08-20 2009-02-26 Wyeth Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
JP5315710B2 (ja) * 2008-02-07 2013-10-16 セントラル硝子株式会社 １−ブロモ−３−フルオロ−５−ジフルオロメチルベンゼンの製造方法
DE102008015033A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung
MX2010009649A (es) * 2008-03-27 2010-12-17 Evotecv Neurosciences Gmbh Metodos para tratar trastornos utilizando un antagonista selectivo del subtipo nr2b de nmda.
MY170610A (en) 2009-02-05 2019-08-20 Takeda Pharmaceuticals Co Pyridazinone compounds
US8883788B2 (en) 2010-08-04 2014-11-11 Takeda Pharmaceutical Company Limited Fused heterocyclic ring compound
WO2012019106A2 (en) * 2010-08-06 2012-02-09 Board Of Regents Of The University Of Nebraska Positive and negative modulators of nmda receptors
WO2013160728A1 (en) 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Dual targeting compounds for the treatment of alzheimer's disease
US9981950B2 (en) * 2014-08-15 2018-05-29 Janssen Pharmaceuticals, Inc. Triazoles as NR2B receptor inhibitors
DE102015011861B4 (de) 2015-09-10 2018-03-01 Rudolf Schindler Neue cyclische Carboxamide als NMDA NR2B Rezeptor Inhibitoren
ES2821010T3 (es) 2015-12-09 2021-04-23 Cadent Therapeutics Inc Moduladores heteroaromáticos del receptor NMDA y usos de los mismos
MA44008A (fr) 2016-02-10 2018-12-19 Janssen Pharmaceutica Nv 1,2,3-triazoles substitués utilisés comme modulateurs de nmda sélectifs de nr2b
JP6850300B2 (ja) 2016-02-18 2021-03-31 シンジェンタ パーティシペーションズ アーゲー 殺有害生物活性ピラゾール誘導体
WO2017158147A1 (en) 2016-03-18 2017-09-21 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO2017158151A1 (en) 2016-03-18 2017-09-21 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途
CA3047403A1 (en) 2016-12-22 2018-06-28 Cadent Therapeutics, Inc. Nmda receptor modulators and uses thereof
EP3774732A4 (en) 2018-04-04 2022-02-09 Janssen Pharmaceutica NV PYRIDINE AND SUBSTITUTED PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
CA3108519A1 (en) 2018-08-03 2020-04-30 Cadent Therapeutics, Inc. Heteroaromatic nmda receptor modulators and uses thereof
CN113993583A (zh) 2019-06-14 2022-01-28 詹森药业有限公司 取代的吡唑并[4,3-b]吡啶及其作为GLUN2B受体调节剂的用途
PH12021552839A1 (en) 2019-06-14 2022-10-03 Janssen Pharmaceutica Nv Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators
EP3982958A1 (en) 2019-06-14 2022-04-20 Janssen Pharmaceutica NV Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators
MX2021015511A (es) 2019-06-14 2022-01-31 Janssen Pharmaceutica Nv Carbamatos de pirazina y sus usos como moduladores del receptor glun2b.
JP2022536773A (ja) 2019-06-14 2022-08-18 ヤンセン ファーマシューティカ エヌ．ベー． 置換ピラゾロピラジン及びｇｌｕｎ２ｂ受容体調節因子としてのそれらの使用
BR112021025132A2 (pt) 2019-06-14 2022-01-25 Janssen Pharmaceutica Nv Carbamatos de piridina e seu uso como moduladores do receptor glun2b
CR20210580A (es) 2019-06-14 2022-01-31 Janssen Pharmaceutica Nv Amidas depirazol-piridina sustituidos y su uso como moduladores del receptor glun2b
CN114478210A (zh) * 2022-02-26 2022-05-13 江苏壹药新材料有限公司 一种7-氯萘-2-甲醛的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4010797A1 (de) * 1990-04-04 1991-10-10 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung
BR9708171A (pt) * 1996-03-08 1999-07-27 Hoffmann La Roche Uso de derivados de 4-fenil-3,6-di-hidro-2h-piridila como bloqueadores de subtipo de receptor nmda
CA2220649C (en) * 1996-12-03 2007-02-13 F. Hoffmann-La Roche Ag 4-hydroxy-piperidine derivatives
US6015824A (en) 1998-02-10 2000-01-18 Hoffmann-La Roche Ag Pyrrolidine and piperidine derivatives and treatment of neurodegenerative disorders
TWI254043B (en) 1999-06-08 2006-05-01 Hoffmann La Roche Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor
EP1070708B1 (en) * 1999-07-21 2004-01-14 F. Hoffmann-La Roche Ag Triazole derivatives
US6339093B1 (en) * 1999-10-08 2002-01-15 Hoffmann-La Roche Inc. Isoquinoline derivatives
CA2404464C (en) 2000-04-20 2008-03-11 F. Hoffmann-La Roche Ag Pyrrolidine and piperidine derivatives and their use for the treatment of neurodegenerative disorders
US6432985B2 (en) 2000-04-25 2002-08-13 Hoffmann-La Roche Inc. Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists
WO2002028814A2 (en) 2000-10-06 2002-04-11 Regents Of The University Of California Nmda receptor channel blocker with neuroprotective activity
CA2381630A1 (en) 2001-04-23 2002-10-23 Leonard Theodore Meltzer Method for preventing dyskinesias
DE10120159A1 (de) 2001-04-25 2002-10-31 Merck Patent Gmbh NMDA-Antagonisten und NMDA-Agonisten zur Behandlung von Suchterkrankungen
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives

Also Published As

Publication number Publication date
WO2003097637A1 (en) 2003-11-27
MXPA04011253A (es) 2005-01-25
MA27117A1 (fr) 2004-12-20
AR040010A1 (es) 2005-03-09
MEP76708A (en) 2011-12-20
DE60306152T2 (de) 2007-04-26
ZA200408789B (en) 2005-12-28
EP1506190A1 (en) 2005-02-16
CN1653062A (zh) 2005-08-10
HK1080845A1 (en) 2006-05-04
RU2317294C2 (ru) 2008-02-20
AU2003242542B2 (en) 2008-10-16
CL2004001251A1 (es) 2005-04-22
DE60306152D1 (de) 2006-07-27
SI1506190T1 (sl) 2006-10-31
PL374224A1 (en) 2005-10-03
CA2485926A1 (en) 2003-11-27
KR100632868B1 (ko) 2006-10-13
US20030229096A1 (en) 2003-12-11
RS98504A (sr) 2006-12-15
CA2485926C (en) 2009-11-24
RU2004136979A (ru) 2005-07-10
BR0311177A (pt) 2005-03-15
TNSN04224A1 (fr) 2007-03-12
DK1506190T3 (da) 2006-10-16
ATE329912T1 (de) 2006-07-15
US7005432B2 (en) 2006-02-28
PT1506190E (pt) 2006-11-30
IL164922A (en) 2012-01-31
ES2265581T3 (es) 2007-02-16
JP2005532326A (ja) 2005-10-27
JP4267569B2 (ja) 2009-05-27
EP1506190B1 (en) 2006-06-14
NZ536310A (en) 2007-08-31
RS51200B (sr) 2010-12-31
NO329605B1 (no) 2010-11-22
KR20040106558A (ko) 2004-12-17
AU2003242542A1 (en) 2003-12-02
CY1105159T1 (el) 2009-11-04
HRP20041060A2 (en) 2005-06-30
CN1312151C (zh) 2007-04-25
NO20044666L (no) 2004-12-15
PL211340B1 (pl) 2012-05-31
IL164922A0 (en) 2005-12-18

Similar Documents

Publication Publication Date Title
HRP20041060A2 (en) (imidazol-1-yl-methyl)-pyridazine as nmda receptor blocker
PL379420A1 (pl) Pochodne blokerów receptora angiotensyny II
SI2208727T1 (sl) Diaril etri kot antagonisti opioidnega receptorja
IL198122A0 (en) Triazole derivatives as tachykinin receptor antagonists
AU2002353081A1 (en) Pulsatile release histamine h2 antagonist dosage forms
PL377517A1 (pl) Modyfikowane na atomie C-9 indazolilopirolotriazyny
AU2003257032A1 (en) Antibodies against c3a receptor
AP2006003840A0 (en) Indole-2-carboxamidine derivatives as NMDA receptor antagonists
AU2003248356A1 (en) Beta3-adrenergic receptor agonists
AU2003294449A1 (en) Cannabinoid receptor ligands
GB0226227D0 (en) Receptors
AU2003278403A1 (en) 1-alkylpiperazinyl-pyrrolidin-2, 5-dione derivatives as adrenergic receptor antagonist
IL173337A0 (en) Receptor
GB0215389D0 (en) Receptor
AU2003281525A1 (en) Serotonin receptor
GB0223399D0 (en) Receptors
AU2003240730A1 (en) Morpholinylmethylureas ccr-3 receptor antagonist
GB0321998D0 (en) Receptor
AU2003236673A1 (en) G protein-coupled receptor variants
AUPS283002A0 (en) Receptor
AU2002338040A1 (en) Receptor antagonist
GB0307100D0 (en) Receptor
GB0329104D0 (en) Receptor
AU2002951108A0 (en) Receptor specific ligands
AU2002305947A1 (en) Piperidine-piperazine ligand for neurotransmitter receptors

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
PPPP Transfer of rights

Owner name: EVOTEC INTERNATIONAL GMBH, DE

ODRP Renewal fee for the maintenance of a patent

Payment date: 20140508

Year of fee payment: 12

PBON Lapse due to non-payment of renewal fee

Effective date: 20150516